Response to Comments: MolDX: Blood Product Molecular Antigen Typing (L38441)

This document is a response-to-comments notice regarding MolDX: Erythrocyte Molecular Antigen Typing (LCD L38441), renamed to MolDX: Blood Product Molecular Antigen Typing. It records the comment period (10/7/2019–11/21/2019), notice start (9/10/2020) and effective date (10/25/2020). No clinical coverage criteria, indications, limitations, documentation requirements, or frequency limits are present in this excerpt; refer to the full LCD L38441 for specific coverage rules.